Effect of Eicosapentaenoic acid on adequate statin therapy in patients with coronary artery disease. Prospective randomized trial.

Effect of Eicosapentaenoic acid on adequate statin therapy in patients with coronary artery disease. Prospective randomized trial. - Effect of Eicosapentaenoic acid on adequate statin therapy in patients with coronary artery disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007956

Enrollment

Registered

2012-05-21

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Add oral EPA 1800 mg daily on the ordinary statin treatment. Ordinary statin treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were; 1. Patients with established coronary artery disease. 2. ALL patients received adequate statin treatment and LDL-Cholesterol was controlled less than 100 mg/dl. 3. Patients had endothelial dysfunction defined as FMD <6%.

Exclusion criteria

Exclusion criteria: The exclusion criteria were; 1. Episode of acute coronary syndrome or revascularization within 3 months. 2. Initiation of ACE-I, ARB, CCB, beta-blockers, antiplatelet drugs, or other lipid-lowering drugs within 3 months. 3. Severe renal and liver dysfunction

Design outcomes

Primary

Measure	Time frame
Change in flow mediated dilation.	—

Secondary

Measure	Time frame
Change in Lipid profiles.	—

Countries

Japan

Contacts

Public ContactKentaro Toyama

Saitama medical center, Saitama medical university Division of cardiology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026